(NASDAQ: BVS) Bioventus's forecast annual revenue growth rate of 6.87% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.06%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.32%.
Bioventus's revenue in 2026 is $568,087,000.On average, 5 Wall Street analysts forecast BVS's revenue for 2026 to be $50,750,199,275, with the lowest BVS revenue forecast at $49,082,945,755, and the highest BVS revenue forecast at $52,868,151,750. On average, 5 Wall Street analysts forecast BVS's revenue for 2027 to be $54,104,663,463, with the lowest BVS revenue forecast at $52,264,447,982, and the highest BVS revenue forecast at $56,595,149,393.
In 2028, BVS is forecast to generate $57,717,739,045 in revenue, with the lowest revenue forecast at $55,952,362,874 and the highest revenue forecast at $60,057,714,807.